However, these p53-activating agents often exhibit dose-limiting adverse effects, which are most-commonly related to gastrointestinal and hematological disorders, and could be caused, at least in part, by elevated MDM2 expression subsequent to p53 activation induced by the small molecules. The gene discussed is TP53; the disease is hematologic disorder.